ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Interleukins"

  • Abstract Number: 2122 • ACR Convergence 2022

    Bimekizumab Treatment Improves Health-Related Quality of Life in Biologic DMARD-Naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies

    Dafna Gladman1, Lars Erik2, Diamant Thaci3, Paolo Gisondi4, Laure Gossec5, M. Elaine Husni6, Alice Gottlieb7, Hiroaki Dobashi8, Barbara Ink9, Deepak Assudani9, Rajan Bajracharya9, Jason Coarse10, Jérémy Lambert11 and William Tillett12, 1Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 2Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, 3Institute and Comprehensive Center for Inflammation Medicine, University Hospital of Lübeck, Lübeck, Germany, 4Dermatology and Venereology, Department of Medicine, Università di Verona, Verona, Italy, Verona, 5Sorbonne Université, Paris, France, 6Cleveland Clinic, Cleveland, OH, 7Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, NY, 8Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, 9UCB Pharma, Slough, United Kingdom, 10UCB Pharma, Raleigh, NC, USA, Raleigh, NC, 11UCB Pharma, Colombes, France, Irigny, France, 12Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

    Background/Purpose: PsA imparts a substantial burden on patient health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition…
  • Abstract Number: 0989 • ACR Convergence 2022

    Regulatory T Cell Defects in SLE and Therapy with a Novel IL-2 Mutein: Phase 1 Clinical Results with Efavaleukin Alfa

    Nandita Sarkar1, Xuguang Hu1, Nadia Tchao1, Richard Furie2, Alan Kivitz3, Stanley B Cohen4 and Kevin Gorski5, 1Amgen Inc., South San Francisco, CA, 2Northwell Health, Great Neck, NY, 3Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, 4Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 5Amgen, Inc., Thousand Oaks, CA

    Background/Purpose: Regulatory T cells (Treg) are critical for maintaining self-tolerance and preventing autoimmunity, and IL-2 is essential for their development, survival and suppressive function. Defects…
  • Abstract Number: 2125 • ACR Convergence 2022

    Effects of Treatment with Risankizumab on Minimal Disease Activity and Disease Activity in Psoriatic Arthritis: An Analysis of the KEEPsAKE-1 and -2 Trials

    Joseph Merola1, Iain B McInnes2, Arthur Kavanaugh3, Peter Nash4, Zhenyi Xue5, Vassilis Stakias6, Ann Eldred7, Sandra Ciecinski8, Kevin Douglas6 and Laura Coates9, 1Harvard Medical School, Brigham and Women's Hospital, Boston, MA, 2Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, 3University of California San Diego, La Jolla, CA, 4School of Medicine, Griffith University, Sunshine Coast, Australia, 5AbbVie, Inc., Wilmington, DE, 6AbbVie, Inc., North Chicago, IL, 7AbbVie, Inc., Lake Bluff, IL, 8AbbVie, Inc., Mettawa, IL, 9Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom

    Background/Purpose: Risankizumab (RZB) is a monoclonal antibody that specifically inhibits interleukin 23.Methods: KEEPsAKE-1 and -2, double-blind, phase 3 trials, evaluated the efficacy of RZB versus…
  • Abstract Number: 1043 • ACR Convergence 2022

    Uveitis in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: Baseline Characteristics and Incidence Rates During Secukinumab and Placebo Comparative Phase: A Post Hoc Analysis

    Jan Brandt-Juergens1, Martin Rudwaleit2, Frank Behrens3, Christopher Ritchlin4, Daniel Peterlik5, Erhard Quebe-Fehling6, Renato Calheiros7 and Atul Deodhar8, 1Rheumatologische Schwerpunktpraxis, Berlin, Germany, 2University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, 3Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, 4Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, 5Novartis Pharma GmbH, Nürnberg, Germany, 6Novartis Pharma AG, Basel, Switzerland, 7Novartis Pharmaceuticals Corp., Hoboken, NJ, 8Oregon Health & Science University, Portland, OR, USA, Portland, OR

    Background/Purpose: Uveitis is one of the most frequently reported extra-musculoskeletal manifestations of axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA).1,2 The prevalence of anterior uveitis is…
  • Abstract Number: 2126 • ACR Convergence 2022

    Impact of Risankizumab on Enthesitis and Dactylitis: Integrated Analysis of the Phase 3, Randomized, Double-Blind KEEPsAKE 1 and 2 Trials

    Shawn Kwatra1, Saakshi Khattri2, Ahmad Amin3, Huzefa Photowala4, Ran Liu4, Byron Padilla5, Blair Kaplan4 and Dennis McGonagle6, 1John Hopkins University, Baltimore, MD, 2Mount Sinai Medical Center, New York, NY, 3Northwestern Medicine Dermatology, Chicago, IL, 4AbbVie, Inc., North Chicago, IL, 5AbbVie, Inc., Waukegan, IL, 6Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Background/Purpose: Psoriatic arthritis (PsA) is a progressive condition with chronic inflammation and joint destruction impacting quality of life.1 Dactylitis and enthesitis are clinically relevant domains…
  • Abstract Number: 1074 • ACR Convergence 2022

    Safety and Efficacy of Dupilumab in Patients with Relapsing and/or Refractory Eosinophilic Granulomatosis with Polyangiitis

    Berengere Molina1, Maria Letizia Urban2, Roberto Padoan3, Pavel Novikov4, Camille Taillé5, Marco Caminati6, Christine Christides7, nicolas schleinitz8, Laura Moi9, Vincent Cottin10, bertrand godeau11, Laurence Bouillet12, Paolo Fraticelli13, Ann Knight14, Jan Walter Schroeder15, Sylvain Marchand-Adam16, Helder Gil17, Elena Gelain18, Giacomo Emmi2 and Benjamin Terrier19, 1Department of Internal Medicine, Cochin Hospital, Paris, France, 2Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 3University of Padova, Padova, Italy, 4Tareev’s Clinic, Sechenov First Moscow State Medical University, Moscow, Russia, 5Pulmonology department, Bichat Hospital, Paris, Ile-de-France, France, 6Verona University Hospital, University of Verona, Verona, Italy, 7Avignon hospital, Avignon, France, 8Aix Marseille university, AP-HM, Marseille, France, 9Centre hospitalier universitaire vaudois, Lausanne, Lausanne, Switzerland, 10Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, 11Department of Internal Medicine, National Referral Center for Adult's Immune Cytopenias, Mondor Hospital, Créteil, France, 12Grenoble University Hospital, Grenoble, France, 13Department of Internal Medicine, Ospedali Riuniti di Ancona, Ancona, Italy, 14Akademiska sjukhuset, Uppsala, Sweden, 15ASST GOM Niguarda, Milano, Italy, 16Tours University Hospital, Tours, France, 17Besancon University Hospital, Besançon, France, 18Meyer Children’s University Hospital of Firenze, Florence, Italy, 19National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is an ANCA-associated vasculitides characterized by asthma, blood and tissue eosinophilia and systemic manifestations. Glucocorticosteroids (GCs)-dependent asthma and/or disabling…
  • Abstract Number: 2148 • ACR Convergence 2022

    Analysis of Serum Proteomics Data Identifies Beta-Defensin 2 as a Predictive Biomarker of Clinical Response to IL-17 Blockade in Psoriatic Arthritis

    Mathias Cardner1, Danny Tuckwell2, Anna Kostikova2, Pascal Forrer3, Richard Siegel2, Alain Marti3, Marc Vandemeulebroecke3 and Enrico Ferrero2, 1Novartis Global Drug Development and Novartis Institutes for BioMedical Research, Basel, Switzerland, 2Novartis Institutes for BioMedical Research, Basel, Switzerland, 3Novartis Global Drug Development, Basel, Switzerland

    Background/Purpose: Despite several effective targeted therapies, biomarkers that predict whether a patient with psoriatic arthritis (PsA) will respond to a particular treatment are currently lacking.Methods:…
  • Abstract Number: 1147 • ACR Convergence 2022

    Transcriptomic Changes Induced by Tocilizumab in Ex-Vivo PBMCs from Patients with GCA in Remission. Predictors of Response

    Marco A Alba1, Roser Alba1, Georgina Espigol Frigolé2, Javier Marco Hernández2, Sergio Prieto2, Marc Corbera-Bellalta3 and Maria C Cid3, 1IDIBAPS, Barcelona, Spain, 2Hospital Clínic de Barcelona, Barcelona, Spain, 3Hospital Clinic, University of Barcelona, Barcelona, Spain

    Background/Purpose: Glucocorticoids (GCs) are only effective therapy able to induce disease remission, but most patients relapse when GC are tapered and suffer from GC-related toxicity.…
  • Abstract Number: 2150 • ACR Convergence 2022

    Cycling vs Swapping Strategies with TNFi and IL-17i in Psoriatic Arthritis: An Observational Retrospective Monocentric Study

    Federica Lumetti1, Alarico Ariani2, Camilla Coccolini3, Carlo Salvarani4 and Gilda Sandri4, 1Rheumatology Unit, AUSL of Modena and Azienda Ospedaliero Universitaria of Modena, Modena, Italy, 2Department of Medicine, Unit of Internal Medicine and Rheumatology, Azienda Ospedaliero Universitaria of Parma, Parma, Emilia-Romagna, Italy, 3Università di Modena e Reggio Emilia, Modena, Italy, 4Rheumatology Unit, Azienda Ospedaliero Universitaria of Modena, Modena, Italy

    Background/Purpose: The therapy of psoriatic arthritis (PsA) was amplified in the last years with the introduction of a large amount of new biologic molecules with…
  • Abstract Number: 1161 • ACR Convergence 2022

    IL-36-receptor Antagonist-Antibodies in Psoriasis and Psoriatic Arthritis

    Marie-Christin Hoffmann1, Natalie Fadle1, Evi Regitz1, Klaus-Dieter Preuss1, Marina Zaks2, Elisabeth Stöger3, Vincent Zimmer4, Philipp Klemm5, Gunter Assmann6, Bernhard Thurner7, Claudia Pföhler8, Joerg Thomas Bittenbring1, Christoph Kessel9 and Lorenz Thurner1, 1José Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany, 2Department of Nephrology and Internal Intensive Care, Charité University Medicine Berlin, Campus Virchow Clinic, Berlin, Germany, 3Evangelische Kliniken Essen-Mitte gGmbH, Evangelische Huyssens-Stiftung Essen-Huttrop, Essen, Germany, Essen, Germany, 4Department of Medicine, Knappschaftsklinikum Saar, Püttlingen, Germany, Department of Medicine II, Saarland University Medical School, Homburg/Saar, Germany, 5Campus Kerckhoff of Justus Liebig University Giessen, Bad Nauheim, Germany, 6Klinik für Rheumatologie und klinische Immunologie, Mühlenkreiskliniken, Johannes Wesling Klinikum Minden, Minden, Germany, Minden, Germany, 7Department of Pediatrics, Klinikum Kempten, Kempten, Germany, 8Department of Dermatology, Saarland University Medical School, Homburg/Saar, Germany, 9Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster, Münster, Germany, Münster, Germany

    Background/Purpose: Psoriasis arthritis is known as a subtype of seronegative spondylarthritis. However, autoantibodies against the receptor antagonist at tumor necrosis factor receptor 1 and 2…
  • Abstract Number: 2153 • ACR Convergence 2022

    Key Differences Between US Rheumatologists’ and Dermatologists’ Management of Psoriatic Arthritis

    Maxine Yarnall, Spherix Global Insights, Exton, PA

    Background/Purpose: The last few years have seen the approval of many new agents for the treatment of psoriatic arthritis (PsA) and psoriasis (PSO), resulting in…
  • Abstract Number: 0026 • ACR Convergence 2022

    Silencing of WISP-2 Induces Inflammatory Mediators and Catabolic Factors in Cartilage

    Clara Ruiz-Fernández1, María González-Rodríguez2, Vera Francisco3, Djedjiga Ait Eldjoudi2, Alfonso Cordero-Barreal2, Yousof Farrag2, Jesús Pino4, Miguel Ángel González-Gay5, Antonio Mera6, Francisca Lago2 and Oreste Gualillo7, 1Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Galicia, Spain, 2Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain, 3Institute of Health Research-INCLIVA, València, Spain, 4Santiago Clinic Hospital CHUS-Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain, 5Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 6Santiago University Clinical Hospital CHUS, Santiago de Compostela, Spain, 7Hospital Clínico Universitario de Santiago, SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago de Compostela, Spain

    Background/Purpose: Wnt-1 inducible signaling pathway protein 2 (WISP-2/CCN5) is an adipokine that has been described as an important mediator of canonical Wnt activation in adipogenic…
  • Abstract Number: 1185 • ACR Convergence 2022

    Interleukin-11 Promotes Fibrosis Through Classic and Trans-signaling Pathway in Systemic Sclerosis

    Wenjing Ye1, Qian Wang1, Li Zhao2, Changcheng Wang3, Dandan Zhang4, Mengyu Zhou4, Fangfang Chen2, Zaihua Zhu2, Weiguo Wang2, Wenyu Guo5, Yun Liu4, Hejian Zou2 and Yu Xue2, 1epartment of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China, 2Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China, 3Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China, 4MOE Key Laboratory of Metabolism and Molecular Medicine, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China, 5Clinical Development, I-Mab Biopharma (Hangzhou) Co., Ltd, Shanghai, China

    Background/Purpose: Interleukin-11 (IL-11) was found significantly upregulated in Systemic sclerosis (SSc), the aim of this study is to explore the pathological role of IL-11 and…
  • Abstract Number: 2209 • ACR Convergence 2022

    Efficacy of Secukinumab in Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis Subtypes of Juvenile Idiopathic Arthritis: Results from a Randomized, Phase 3 Study

    Hermine Brunner1, Elena Chertok2, Joke Dehoorne3, Gerd Horneff4, Tilmann Kallinich5, Ingrid Louw6, Maria Alessio7, Sandrine Compeyrot-Lacassagne8, Bernard Lauwerys9, Neil Martin10, Katherine Marzan11, W Patrick Knibbe12, Ruvie Martin13, Xuan Zhu14, sarah whelan15, Luminita Pricop16, Daniel Lovell17, Alberto Martini18 and Nicola Ruperto19, 1Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH, 2Voronezh State Medical University, Voronezh, Russia, 3University Hospital Gent, Gent, Belgium, 4Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, 5Charité - Universitätsmedizin Berlin, Nuremberg, Germany, 6Panaroma Medical Centre, Cape Town, South Africa, 7Policlinico Federico II di Napoli, Napoli, Italy, 8Great Ormond Street Hospital for Children, London, United Kingdom, 9Cliniques Universitaires Saint-Luc, Brussels, Belgium, 10Royal Hospital for Children, Glasgow, Scotland, United Kingdom, 11Children's Hospital Los Angeles, Los Angeles, CA, 12St. Luke's Hospital System, Meridian, ID, 13Novartis Pharmaceutical Corporation, East Hanover, NJ, 14Novartis Pharmaceuticals Corporation, Basking Ridge, NJ, 15Novartis Ireland Ltd, Crumlin, Dublin, Ireland, 16Novartis Pharmaceuticals Corporation, East Hanover, NJ, 17Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 18Istituto Giannina Gaslini, Genova, Italy, 19IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy

    Background/Purpose: Juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) represent pediatric counterparts of adult non-radiographic axial spondyloarthritis and psoriatic…
  • Abstract Number: L19 • ACR Convergence 2021

    Secukinumab in Giant Cell Arteritis: A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial

    Nils Venhoff1, Wolfgang Schmidt2, Raoul Bergner3, Jürgen Rech4, Leonore Unger5, Hans-Peter Tony6, Meryl Mendelson7, Christian Sieder8, Meron Maricos8 and Jens Thiel9, 1Department of Rheumatology and Clinical Immunology, Vasculitis Center Freiburg, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany, 2Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Lindenberger Weg 19, 13125 Berlin, Germany, Berlin, Germany, 3Medizinische Klinik A, Klinikum der Stadt Ludwigshafen, Ludwigshafen, Germany, 4Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054,, Erlangen, Germany, 5Medical Department 1, Städtisches Klinikum Dresden, Dresden, Germany, 6Department of Medicine 2, Rheumatology and Clinical Immunology Oberduerrbachertstr. 697080, Wuerzburg, Germany, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, 8Novartis Pharma GmbH, Nuremberg, Germany, 9Department of Rheumatology and Clinical Immunology, Vasculitis Center Freiburg, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany; Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

    Background/Purpose: Little is known about glucocorticoid-sparing agents in giant cell arteritis (GCA) except for IL-6 inhibition. Secukinumab (SEC) has shown significant improvements in the signs…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 11
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology